ECSP088430A - Diarilurea para el tratamiento de hipertensión pulmonar - Google Patents

Diarilurea para el tratamiento de hipertensión pulmonar

Info

Publication number
ECSP088430A
ECSP088430A EC2008008430A ECSP088430A ECSP088430A EC SP088430 A ECSP088430 A EC SP088430A EC 2008008430 A EC2008008430 A EC 2008008430A EC SP088430 A ECSP088430 A EC SP088430A EC SP088430 A ECSP088430 A EC SP088430A
Authority
EC
Ecuador
Prior art keywords
treatment
pulmonary hypertension
diarilure
methylamide
fluorophenoxy
Prior art date
Application number
EC2008008430A
Other languages
English (en)
Inventor
Bernd Riedl
Joachim Huetter
Peter Sandner
Hanna Tinel
Martina Klein
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of ECSP088430A publication Critical patent/ECSP088430A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas para el tratamiento, prevención o control de hipertensión pulmonar que comprenden metilamida del ácido 4{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridina-2-carboxílico, opcionalmente combinada con al menos un agente terapéutico adicional.
EC2008008430A 2005-11-10 2008-05-07 Diarilurea para el tratamiento de hipertensión pulmonar ECSP088430A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05024509 2005-11-10
EP05027450 2005-12-15
EP06012234 2006-06-14

Publications (1)

Publication Number Publication Date
ECSP088430A true ECSP088430A (es) 2008-07-30

Family

ID=37622057

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008430A ECSP088430A (es) 2005-11-10 2008-05-07 Diarilurea para el tratamiento de hipertensión pulmonar

Country Status (18)

Country Link
US (1) US20100035888A1 (es)
EP (1) EP1948170A1 (es)
JP (1) JP5084736B2 (es)
KR (1) KR20080067000A (es)
AR (1) AR057849A1 (es)
AU (1) AU2006312714A1 (es)
BR (1) BRPI0618522A2 (es)
CA (1) CA2628849A1 (es)
CR (1) CR9953A (es)
EC (1) ECSP088430A (es)
GT (1) GT200800058A (es)
IL (1) IL191178A0 (es)
NO (1) NO20082498L (es)
PE (1) PE20070806A1 (es)
SV (1) SV2009002900A (es)
TW (1) TW200733961A (es)
UY (1) UY29903A1 (es)
WO (1) WO2007054216A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE538794T1 (de) * 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
US7838541B2 (en) 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
NZ589793A (en) * 2003-02-21 2011-12-22 Resmed Ltd Nozzle configuration of nasal cushion for respiratory assistance mask
UY28213A1 (es) * 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
WO2004113274A2 (en) * 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
RS52625B (sr) 2003-07-23 2013-06-28 Bayer Healthcare Llc Fluoro supstituisana omega-karboksiaril difenil urea za lečenje i prevenciju bolesti i stanja bolesti
KR101381454B1 (ko) * 2004-09-29 2014-04-04 바이엘 인텔렉쳐 프로퍼티 게엠베하 열역학적으로 안정한 형태의 ｂａｙ 43-9006 토실레이트
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
EP2129376B1 (en) * 2007-01-19 2013-07-24 Bayer HealthCare LLC Treatment of cancers with acquired resistance to KIT inhibitors
EP2296641A1 (en) * 2008-06-25 2011-03-23 Bayer Schering Pharma Aktiengesellschaft Diaryl urea for treating heart failure
CA2796744A1 (en) * 2010-04-17 2011-10-20 Bayer Healthcare Llc Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
EA201300420A1 (ru) 2010-10-01 2013-09-30 Байер Интеллектчуал Проперти Гмбх Комбинации, которые содержат замещенный n-(2-ариламино) арилсульфонамид
GB2503181A (en) * 2011-03-14 2013-12-18 Cellworks Res India Private Ltd Compositions, process of preparation of said compositions and method of treating inflammatory diseases
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838541B2 (en) * 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
JP4429732B2 (ja) * 2002-04-10 2010-03-10 バージニア コモンウェルス ユニバーシティー 癌の処置におけるグリベック（ｓｔｉ５７１）とサイクリン依存性キナーゼインヒビター、とりわけフラボピリドールとの組合せ剤
WO2004113274A2 (en) * 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
RS52625B (sr) * 2003-07-23 2013-06-28 Bayer Healthcare Llc Fluoro supstituisana omega-karboksiaril difenil urea za lečenje i prevenciju bolesti i stanja bolesti
WO2006091542A2 (en) * 2005-02-22 2006-08-31 Cedars-Sinai Medical Center Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier

Also Published As

Publication number Publication date
CA2628849A1 (en) 2007-05-18
EP1948170A1 (en) 2008-07-30
JP2009514910A (ja) 2009-04-09
IL191178A0 (en) 2009-08-03
AR057849A1 (es) 2007-12-19
NO20082498L (no) 2008-08-07
AU2006312714A1 (en) 2007-05-18
US20100035888A1 (en) 2010-02-11
CR9953A (es) 2008-10-08
WO2007054216A1 (en) 2007-05-18
KR20080067000A (ko) 2008-07-17
UY29903A1 (es) 2007-06-29
JP5084736B2 (ja) 2012-11-28
SV2009002900A (es) 2009-04-28
BRPI0618522A2 (pt) 2011-09-06
PE20070806A1 (es) 2007-09-29
GT200800058A (es) 2010-02-23
TW200733961A (en) 2007-09-16

Similar Documents

Publication Publication Date Title
ECSP088430A (es) Diarilurea para el tratamiento de hipertensión pulmonar
HN2005000255A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
CU20080082A7 (es) Diarilureas para el tratamiento de hipertensión pulmonar
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
BRPI0520669A2 (pt) dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
NO20083836L (no) N-hydroksyakrylamidforbindelser
BR112015023349A2 (pt) composto, composição farmacêutica, e, método de tratamento de uma doença, condição de saúde ou distúrbio
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
CL2007003341A1 (es) Compuestos derivados de imidazotriazinas; composicion farmaceutica, util para el tratamiento del cancer, arteroesclerosis y enfermedades cardiovasculares entre otras.
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
BR0310099A (pt) método para tratar dislipidemia ou uma doença associada com a dislipidemia
BRPI0713306A8 (pt) Composição farmacêutica compreendendo amlodipina e losartan
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
BRPI0807528A2 (pt) Composições lubrificantes pessoais complementares
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
NO20076405L (no) Anvendelse av 24-nor-UDCA
MX2022004882A (es) Composicion farmaceutica que comprende selexipag.
CY1115384T1 (el) Αντι-φλεγμονωδης συνθεση
DOP2007000073A (es) Compuestos para tratar la hipertensión pulmonar
WO2003105751A3 (en) Novel curcumin derivatives
DE602005016803D1 (de) Zusammensetzungen mit strontium und vitamin d und ihre verwendungen
BRPI0607003A2 (pt) forma de dosagem com liberação sustentada e método para liberação sustentada de um composto de pirazina substituìda
CL2008000949A1 (es) Compuestos derivados de 2,3-benzodiazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos psicoticos.
BR112012024346A2 (pt) agente terapêutico ou agente profilático para a doença de alzheimer
DOP2006000244A (es) Diarilurea para el tratamiento de hipertensión pulmonar